Cytogenix: Wann, wenn nicht jetzt..... - 500 Beiträge pro Seite

[morchel]

Ich bin bekennender Cytogenix Aktionär. Heute brachte das Unternehmen eine weiter bahnbrechende Nachricht:

CytoGenix Completes Second Round of Pre-Clinical Anti-Sepsis Animal Studies

2004-05-06 10:10 ET - News Release

HOUSTON -- (Business Wire) -- May 6, 2004

CytoGenix, Inc. (OTCBB:CYGX) announced the successful
completion of the second round of pre-clinical animal studies,
demonstrating that the company`s DNA anti-bacterial compound is
effective in controlling the growth of "wild" strain of bacteria like
those that cause infection and sepsis in people.
Dr. Yin Chen, CytoGenix Vice President of Research and
Development, stated, "The result of this study is very significant
because it shows that the compound is able to kill wild-type bacteria
in a living animal. These wild strains have thicker cell walls and are
much more difficult to kill than their laboratory cousins. The next
steps involve pharmacological studies to determine safe dosage and
toxicology studies in larger animals."
Dr. Malcolm Skolnick, CytoGenix Chairman and CEO, states,
"Developing a compound that quickly kills dangerous life-threatening
bacteria is a significant advance in medical research accomplished by
a small enterprise such as ourselves and is a harbinger of the future
of DNA medicine. Our ssDNA expression technology is universal, and we
have several other products against infectious diseases in
pre-clinical development."
The Centers for Disease Control report 700,000 cases and 215,000
deaths annually in the U.S. from severe sepsis. This week, CBS 60
Minutes featured a report on the increasing danger of MRSA and other
antibiotic-resistant pathogens, including those that result in
sepsis. Traditional antibiotic therapy has become ineffective because
the sepsis-causing pathogens have mutated and developed defenses
against all but the most powerful and expensive treatments. Care of
people with sepsis costs about $50,000 per case, resulting in an
economic burden of nearly $17 billion a year.
CytoGenix, Inc. is a biopharmaceutical company that develops and
markets innovative products and services based on its proprietary DNA
expression technology. CytoGenix has products in pre-clinical
development, including, anti-herpes, anti-psoriasis and
anti-inflammatory topical creams. The company owns a US patent for its
core DNA expression technology and has 40 international or US pending
patent applications.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the company`s filings with the
Securities and Exchange Commission. Additional information about
CytoGenix and its technology is found on the website at
www.cytogenix.com.
Contacts:

For CytoGenix, Inc.
Juan Ferreira, 407-774-9949

In dieser firma schlummert mehr Potential als in mancher NASDAQ Biotech Firma

morchel

[waldy40]

Die News auf Deutsch:

CytoGenix schließt zweite Runde präklinischer Anti-Sepsis Tierstudien ab

CytoGenix (WKN 922173) verkündet den erfolgreichen Abschluss der zweiten Runde vorklinischer Tierstudien, die zeigen, dass der antibakterielle DNS Wirkstoff des Unternehmens effektiv in der Wachstumskontrolle von wilden Bakteriensträngen ist, die bei Menschen für Infektionen und Sepsis verantwortlich ist.

Dr. Yin Chen, CytoGenix Vize Präsident für Forschung und Entwicklung kommentierte: “Das Ergebnis dieser Studie ist sehr bedeutend, weil es zeigt, dass der Wirkstoff Bakterien wilden Typs in einem lebenden Tier abtöten kann. Diese wilden Stränge haben dickere Zellwände und sind viel schwerer abzutöten als ihre Laborverwandten. Die nächsten Schritte umfassen pharmakologische Studien, um sichere Dosierungen zu bestimmen und toxikologische Studien in größeren Tieren.“

Dr. Malcolm Skolnick, CytoGenix’ Aufsichtsratsvorsitzender und CEO kommentiert: „Die Entwicklung eines Wirkstoffs, der gefährliche lebensbedrohliche Bakterien schnell und effektiv abtötet, ist ein signifikanter Fortschritt in der medizinischen Forschung, der von einem kleinen Unternehmen wie unserem erzielt wurde, und ein Vorbote der Zukunft der DNS Medizin. Unsere Einzelstrang DNS Expressionstechnologie ist universell und wir haben viele andere Produkte gegen infektiöse Krankheiten in der vorklinischen Entwicklung.“

Die Zentren für Krankheitskontrolle in den USA berichten von 700.000 Fällen und 215.000 Todesfällen jährlich durch schwere Sepsis. Diese Woche berichte CBS in einem 60-minütigen Report über die steigende Gefahr durch MRSA und andere Antibiotika resistente Pathogene einschließlich solchen, die zu Sepsis führen. Die traditionelle Antibiotikatherapie ist unwirksam geworden, weil die Sepsis verursachenden Pathogene mutierten und Abwehrmechanismen gegen alle Behandlungsformen ausser die stärksten und teuersten entwickelt haben. Die Pflege von Menschen mit Sepsis kostet etwa 50.000 Dollar pro Fall und führt zu einer ökonomischen Last von fast 17 Mrd. Dollar pro Jahr.

Quelle: http://www.topsmallcaps.com/deutsch/content_updates.php

[morchel]

Top Firma die sicherlich ihren Weg machen wird!

morchel

[alexis74]

leichte kursgewinne, aber scheint für die Amis nicht besonders interessant zu sein die News...

[crashpoet]

Hat jemand irgendeine Ahnung, was da los ist? sieht langsam wirklich unschön aus.

[crashpoet]

CytoGenix Announces Successful Completion of Pre-Clinical Anti-Herpes Safety Studies

HOUSTON--(BUSINESS WIRE)--Aug. 3, 2004--CytoGenix, Inc. (OTCBB:CYGX) announced the successful completion of pre-clinical animal safety studies. These standard studies show that the company`s lead DNA anti-herpes topical compound is safe in three species of animals. A third party laboratory conducted the tests operating under FDA Good Laboratory Practices (GLP) regulations and following United States Pharmacopeia (USP) testing standards for topical products.

Dr. Malcolm Skolnick, CytoGenix, Chairman and CEO, states "We are keenly aware of the urgent need for this product. This accomplishment brings us one-step closer to obtaining FDA authorization to conduct clinical trials of our anti-herpes cream. Rarely does a week go by without receiving an email or telephone call from a herpes sufferer contacting us about the availability of this product. Our anti-herpes cream is designed to be effective against both labial (cold sores) and genital herpes."

Genital herpes is an epidemic in the US and other parts of the world reports the US Centers for Disease Control (CDC) "Genital herpes--herpes simplex virus type two (HSV-2)--is one of the most common sexually transmitted diseases in the United States, with as many as one million people becoming infected each year. While genital herpes continues to spread across all social, economic, racial and ethnic boundaries, prevalence of infection increased most dramatically in teens and young adults. The disease is potentially fatal in newborns and is a major cause of infant blindness. Herpetic infections increase the risk of contracting HIV and can be particularly severe in people with HIV infection. HSV-2 infection is more common in women (approximately one out of four women) than in men (almost one out of five)."

CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis, anti-inflammatory topical creams and antibacterial compounds. The company owns a US patent for its core DNA expression technology and has over 40 international or US pending patent applications.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.

CONTACT: CytoGenix, Inc.Juan Ferreira, 407-774-9949

SOURCE: CytoGenix, Inc.

[crashpoet]

Ui, das hört sich gar nicht gut an...

CYGX: Lopez, Blevins, Bork Hired As Acct - Going Concern [delayed]


Ridgeland, MS, AUG 23, 2004 (EventX/Knobias.com via COMTEX) -- Cytogenix Inc (OTCBB : CYGX) filed an 8-K on 8/23, in which the Company reported that Malone & Bailey, PLLC was dismissed on August 19, 2004 as its independent auditors. Malone & Bailey`s report dated March 22, 2004, on the balance sheet of the Company as of December 31, 2003, and the related statements of operations, stockholders` equity, and cash flows for each of the two years then ended, did not contain an adverse opinion or disclaimer of opinion, or qualification or modification as to uncertainty, audit scope, or accounting principles, except that the report indicated that the Company has suffered recurring losses and its need to raise additional capital that raise substantial doubt about its ability to continue as a going concern.

Lopez, Blevins, Bork & Associates, L.L.P. was engaged on August 19, 2004 as CytoGenix, Inc.`s principal accountant to audit the financial statements.

GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by at least 10 minutes. To get all Knobias alerts in real-time daily, visit www.knobias.com/cmtx

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.


CONTACT: Knobias.com, LLC
601-978-3399
601-978-3675
[e-mail]
www.knobias.com/cmtx


Copyright 2004 Knobias.com, LLC, All rights reserved.

-0-

[crashpoet]

CytoGenix Inc. Files U.S. Patent Application for New Class of Antibacterial Agent

HOUSTON--(BUSINESS WIRE)--Sept. 30, 2004--CytoGenix Inc. (OTCBB:CYGX) announces the filing on Sept. 28, 2004, of a patent application with the U.S. Patent and Trademark Office for an invention titled A Novel Genomic Approach Identifies Bacterial DNA-Dependent RNA Polymerase as the Target of an Antibacterial Oligodeoxynucleotide, RBL1.

The rapid emergence of antibiotic-resistant bacteria strains has created an urgent need for new classes of antimicrobial compounds with entirely new mechanisms of action. CytoGenix scientists have invented a method to rapidly screen and identify bacterial gene targets that when silenced, stop the growth of pathogens. They have demonstrated that short pieces of DNA have activity against several species of Gram-positive and Gram-negative organisms. This is a powerful technology for developing highly specific and efficacious non-resistant antimicrobial agents.

The genomic screening method itself is a powerful tool for identifying potential drug targets for many diseases and disorders. CytoGenix researchers are using this method to identify cancer and other infectious disease gene targets.

Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "This patent embodies one use of this very powerful technology. Combating antibiotic-resistant bacteria is a critical unmet medical need. We believe that this technology will lead us to important advances in discovering new antimicrobial agents."

"Another important feature of this screening technology is that it has broad application to identifying other disease-related gene targets. Our strategy is to identify targets against diseases and disorders which have few if any treatment options," adds Dr. Skolnick.

CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued U.S. patent and over 40 international or U.S. pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.

CONTACT: CytoGenix Inc., HoustonJuan Ferreira, 407-774-9949
www.cytogenix.com

SOURCE: CytoGenix Inc.

[crashpoet]

CytoGenix Inc. Invents Revolutionary Large-Scale Manufacturing Process for High-Purity DNA

HOUSTON--(BUSINESS WIRE)--Dec. 14, 2004--CytoGenix Inc. (OTCBB:CYGX) announces the filing of a patent application with the US Patent and Trademark Office for an invention titled "Chemo-Enzymatic Synthesis of DNA and Uses Thereof." This new technology is a significant advance and a big step towards making DNA medicines a reality. The limited supply and high cost of FDA-approved DNA has stifled the development of powerful DNA vaccines and cancer immunotherapy drugs.

Currently, manufacturers use large fermentation vats of cloned E. coli bacteria to produce DNA by culturing, then rupturing the bacteria to extract the DNA. This process produces great quantities of toxic bacterial contaminants. Sophisticated and expensive purification methods are necessary to remove these toxins, driving the cost of FDA-approved DNA to as much as $250,000 a gram or $250,000,000 a kilogram.

CytoGenix` breakthrough synthesis technology does not use bacteria and therefore produces no bacterial toxins. Gram or greater quantities of very high purity DNA can now be produced in test tubes or flasks in laboratories at a fraction of the time and cost of DNA manufactured using traditional bioprocess methods.

Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "Once you eliminate the bacteria, the scale of production and related costs of DNA come way down. This technology transcends economic implications. More importantly, we have introduced a fundamental improvement to the science of making DNA. For example, DNA vaccines are made of DNA `rings` called plasmids. Scientists design these plasmids to contain instructions that `prompt` the immune system to identify and destroy a viral or bacterial pathogen, such as those that cause AIDS, SARS or influenza."

"Along with the therapeutic DNA, the traditional bacteria-based technology requires that the plasmid contain DNA `instructions` for its replication in E. coli as well. These extraneous bacterial genes are not entirely benign and can elicit serious side effects. By eliminating the need for this extra DNA, the plasmids are significantly smaller and safer, thus enabling greater drug concentrations if required. We believe that by eliminating these extra pieces in the DNA plasmid, scientists will now have much more freedom and control in designing better and safer DNA drugs."

"We will use this technology to reduce the costs of the DNA needed for the clinical trials of our herpes anti-viral and anti-inflammatory topical products as well as making the technology available to others through licensing or contract manufacturing," adds Dr. Skolnick.

CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company`s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.

CONTACT: CytoGenix Inc.Juan Ferreira, 407-774-9949

SOURCE: CytoGenix Inc.